A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors

The main purpose of this study is to test the safety of the investigational drug, BMS-986340, administered alone and in combination with nivolumab. This study will investigate how patients with selected advanced solid tumors tolerate these drugs to identify the highest tolerable dose or the most suitable dose, explore any changes in your tumor, and your general health after receiving multiple doses of BMS-986340 alone or together with nivolumab. BMS-986340 is an immunotherapy antibody and an investigational research drug. Investigational drugs are drugs that are not yet approved by the Food and Drug Administration (FDA) in the United States (US) or by health authorities in other countries. An antibody is a type of protein that your immune system uses to find and destroy infections and potentially harmful cells or particles. An immunotherapy is a treatment that acts by enhancing the function of your immune system. Nivolumab (OPDIVO®), is another immunotherapy antibody that is approved in multiple countries, including the United States (US, Dec-2014), the European Union (EU, Jun-2015), and Japan (Jul-2014), for the treatment of certain types of cancer, its use in combination with BMS-986340 is considered investigational.

Are you Eligible? (Inclusion Criteria)

• you are at least 18 years or older
• you have non-small cell lung cancer (NSCLC), Microsatellite Stable colorectal cancer (MSS-CRC) squamous cell cancer of the head and neck (SCCHN), colorectal cancer, gastric or gastroesophageal junction adenocarcinoma or cervical cancer (SCC or adenocarcinoma)